Effectiveness of meningococcal serogroup C vaccine programmes
Since the introduction of monovalent meningococcal serogroup C (MenC) glycoconjugate
(MCC) vaccines and the implementation of national vaccination programmes, the incidence …
(MCC) vaccines and the implementation of national vaccination programmes, the incidence …
An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine
P Keshavan, M Pellegrini… - Expert Review of …, 2018 - Taylor & Francis
Introduction: Menveo, quadrivalent meningococcal ACWY-CRM conjugate vaccine, was first
licensed in 2010 in the United States and has a long track record of immunogenicity and …
licensed in 2010 in the United States and has a long track record of immunogenicity and …
[HTML][HTML] Antibody persistence and booster responses 24–36 months after different 4CMenB vaccination schedules in infants and children: a randomised trial
F Martinón-Torres, AC Martinez, R Simkó, PI Marquez… - Journal of infection, 2018 - Elsevier
Abstract Objectives This phase IIIb, open-label, multicentre, extension study (NCT01894919)
evaluated long-term antibody persistence and booster responses in participants who …
evaluated long-term antibody persistence and booster responses in participants who …
Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries
MK Taha, J Gaudelus, AE Deghmane… - Human vaccines & …, 2020 - Taylor & Francis
In France, the incidence of invasive meningococcal disease (IMD) is around 1/100,000, with
the following trends over the 2011–2018 period: a leading role of group B in subjects< 15 …
the following trends over the 2011–2018 period: a leading role of group B in subjects< 15 …
Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY …
T Vesikari, A Forsten, V Bianco… - Human Vaccines & …, 2016 - Taylor & Francis
We studied the persistence of serum bactericidal antibody using rabbit and human
complement (rSBA/hSBA, cut-offs 1: 8) 5 y after a single dose of meningococcal serogroups …
complement (rSBA/hSBA, cut-offs 1: 8) 5 y after a single dose of meningococcal serogroups …
[HTML][HTML] Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 …
Background 4CMenB is immunogenic in infants and toddlers. We assessed persistence of
human complement serum bactericidal activity (hSBA) following a fourth dose administered …
human complement serum bactericidal activity (hSBA) following a fourth dose administered …
An overview of meningococcal disease in India: knowledge gaps and potential solutions
TJ John, S Gupta, AJ Chitkara, AK Dutta, R Borrow - Vaccine, 2013 - Elsevier
The Global Meningococcal Initiative (GMI) consists of an international group of scientists and
clinicians, with expertise in meningococcal immunology, epidemiology, public health and …
clinicians, with expertise in meningococcal immunology, epidemiology, public health and …
The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative
MAP Safadi, LEE De Los Monteros… - Expert review of …, 2013 - Taylor & Francis
The Global Meningococcal Initiative (GMI) is an international group of scientists and
clinicians with expertise in meningococcal disease (MD). It promotes MD prevention through …
clinicians with expertise in meningococcal disease (MD). It promotes MD prevention through …
A decade of fighting invasive meningococcal disease: a narrative review of clinical and real-world experience with the MenACWY-CRM conjugate vaccine
Y Ruiz Garcia, V Abitbol, M Pellegrini… - Infectious Diseases and …, 2022 - Springer
Abstract The quadrivalent A, C, W and Y meningococcal vaccine conjugated to nontoxic
mutant of diphtheria toxin (MenACWY-CRM) has been licensed since 2010 for the …
mutant of diphtheria toxin (MenACWY-CRM) has been licensed since 2010 for the …
Five-year antibody persistence and booster response after 1 or 2 doses of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in healthy children
NP Klein, Y Baine, D Kolhe, CI Baccarini… - The Pediatric …, 2016 - journals.lww.com
Background: We evaluated antibody persistence up to 5 years postvaccination with a
quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine …
quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine …